Peptic Ulcers Pipeline Insight 2025: Emerging Therapies and Clinical Trials Shaping Next-Generation Peptic Ulcer Disease Treatments | DelveInsight

DelveInsight's "Peptic Ulcers - Pipeline Insight, 2025" examines over 8+ therapies in development for peptic ulcer disease, a condition affecting millions worldwide with peptic ulcer disease symptoms such as abdominal pain, bloating, nausea, and gastrointestinal bleeding. Despite widespread use of existing peptic ulcer disease treatments, including proton pump inhibitors, H2 blockers, and antibiotics for H. pylori eradication, patients with recurrent or complicated peptic ulcers continue to face significant unmet needs, highlighting the demand for innovative peptic ulcer treatment strategies.

The peptic ulcers pipeline is diversifying with next-generation therapies aimed at improving mucosal protection, accelerating ulcer healing, and reducing recurrence. Key investigational approaches include gastroprotective agents, novel peptic ulcer disease medications, microbiome-modulating therapies, and combination regimens targeting resistant H. pylori infections. These advances are designed to complement current peptic ulcer disease medical procedures and standard pharmacologic care, offering enhanced efficacy and better patient adherence compared to conventional peptic ulcer treatments.

With peptic ulcer clinical trials spanning small molecules, biologics, and novel combination therapies, the therapeutic focus is shifting toward precision-targeted interventions. As these candidates progress through late-stage development, the peptic ulcer treatment landscape is expected to evolve beyond traditional medications, moving toward integrated approaches that combine innovative therapies with established peptic ulcer disease treatments to improve long-term outcomes, reduce recurrence, and address the full spectrum of peptic ulcer disease symptoms.

Interested in learning more about the current treatment landscape and the key drivers shaping the Peptic Ulcers pipeline? Click here: https://www.delveinsight.com/report-store/peptic-ulcers-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Peptic Ulcers Pipeline Report
• DelveInsight's Peptic Ulcers pipeline analysis depicts a strong space with 8+ active players working to develop 8+ pipeline drugs for Peptic Ulcers treatment.
• The leading Peptic Ulcers companies include Daewoong Pharmaceutical, HK inno.N Corporation, PharmaKing, Recce Pharmaceuticals, Sequella, Shandong Luoxin Pharmaceutical, RaQualia Pharma, Sihuan Pharmaceutical Holdings Group, Sinil Pharmaceutical, Kindred Biosciences, and others are evaluating their lead assets to improve the Peptic Ulcers treatment landscape.
• Key Peptic Ulcers pipeline therapies in various stages of development include Fexuprazan, Tegoprazan, PMK S005, R435, SQ109, Anaprazole, SI-001002, KIND-014, and others.
• In April-June 2024, a multicenter randomized controlled trial (TOP study) compared over-the-scope (OTS) clips versus through-the-scope (TTS) clips as first-line endoscopic therapy for high-risk peptic ulcer bleeding and reported higher initial hemostasis and overall clinical success with OTS devices, an advance for interventional management of bleeding peptic ulcers.
• In 2024-2025, multiple clinical studies and meta-analyses showed improved H. pylori eradication rates using vonoprazan-based regimens (vonoprazan + amoxicillin ± other agents) versus traditional PPI regimens, supporting vonoprazan as an important new peptic ulcer disease medication option for infection-driven ulcers.

Request a sample and discover the recent breakthroughs happening in the Peptic Ulcers pipeline landscape at https://www.delveinsight.com/report-store/peptic-ulcers-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Peptic Ulcers Overview
Peptic ulcer disease (PUD) is a common gastrointestinal condition characterized by open sores or ulcers that develop on the lining of the stomach or the upper part of the small intestine. Symptoms of peptic ulcer disease often include burning stomach pain, bloating, nausea, and in severe cases, bleeding. The condition can be caused by factors such as Helicobacter pylori infection, long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs), stress, and lifestyle habits. Diagnosing peptic ulcers typically involves a combination of symptom evaluation, medical procedures like endoscopy, and testing for H. pylori infection.

Treatment for peptic ulcer disease focuses on relieving symptoms, promoting healing, and preventing complications. Peptic ulcer disease treatments commonly include medications such as proton pump inhibitors (PPIs), H2 blockers, and antibiotics when H. pylori infection is present. Lifestyle changes, including diet modification and avoiding NSAIDs, are also important in managing the condition. In rare cases, peptic ulcer disease medical procedures may be required to treat complications like bleeding or perforation. Overall, timely diagnosis and appropriate treatment of peptic ulcers significantly improve patient outcomes and quality of life.

Find out more about Peptic Ulcers medication at https://www.delveinsight.com/report-store/peptic-ulcers-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Peptic Ulcers Treatment Analysis: Drug Profile
Fexuprazan: Daewoong Pharmaceutical
Fexuprazan, developed by Daewoong Pharmaceutical, is a novel potassium-competitive acid blocker (P-CAB) that reversibly inhibits the proton pump responsible for gastric acid secretion in the canalicular membrane. As a next-generation alternative to proton pump inhibitors (PPIs), which are commonly used to treat gastroesophageal reflux disease (GERD), Fexuprazan is currently undergoing Phase III clinical trials for the treatment of peptic ulcers.

KFP-H008: Jiangsu Carephar Pharmaceuticals
KFP-H008, developed by Jiangsu Carephar Pharmaceuticals, is another potassium-competitive acid blocker in development. It is presently in Phase III clinical trials targeting the treatment of duodenal ulcers.

Learn more about the novel and emerging Peptic Ulcers pipeline therapies at https://www.delveinsight.com/report-store/peptic-ulcers-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Peptic Ulcers Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

By Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Scope of the Peptic Ulcers Pipeline Report
• Coverage: Global
• Key Peptic Ulcers Companies: Daewoong Pharmaceutical, HK inno.N Corporation, PharmaKing, Recce Pharmaceuticals, Sequella, Shandong Luoxin Pharmaceutical, RaQualia Pharma, Sihuan Pharmaceutical Holdings Group, Sinil Pharmaceutical, Kindred Biosciences, and others.
• Key Peptic Ulcers Pipeline Therapies: Fexuprazan, Tegoprazan, PMK S005, R435, SQ109, Anaprazole, SI-001002, KIND-014, and others.

To dive deep into rich insights for drugs used for Peptic Ulcers treatment, visit: https://www.delveinsight.com/report-store/peptic-ulcers-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Peptic Ulcers Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Peptic Ulcers Pipeline Therapeutics
6. Peptic Ulcers Pipeline: Late-Stage Products (Phase III)
7. Peptic Ulcers Pipeline: Mid-Stage Products (Phase II)
8. Peptic Ulcers Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.